Drug Profile

JAB BX 300

Alternative Names: JAB-BX-300

Latest Information Update: 01 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jacobio Pharmaceuticals
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Leukaemia inhibitory factor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

04 Apr 2023 Preclinical trials in Solid tumours in China (Parenteral) prior to April 2023
04 Apr 2023 The Center for Drug Evaluation of the National Medical Products Administration (NMPA) of China approves IND application for JAB BX300 in Solid tumours
04 Apr 2023 Jacobio Pharma plans a phase I/IIa trial for Solid tumours (Late-stage disease) in China (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com